Gap Junction Enhancer As an Anti-Cancer Agent Via Gjic-Independent and -Dependent Pathways
Total Page:16
File Type:pdf, Size:1020Kb
GAP JUNCTION ENHANCER AS AN ANTI-CANCER AGENT VIA GJIC-INDEPENDENT AND -DEPENDENT PATHWAYS by YING DING B.E., Tianjin University, Tianjin, China, 2004 B.B.A., Tianjin University, Tianjin, China, 2004 M.S., Tianjin University, Tianjin, China, 2007 AN ABSTRACT OF A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Biochemistry and Molecular Biophysics College of Arts and Sciences KANSAS STATE UNIVERSITY Manhattan, Kansas 2013 Abstract Gap junctions (GJ) are intercellular channels connecting adjacent cells, allowing small molecules to transport between cells, thereby maintaining all homeostasis. Loss of gap junctional intercellular communication (GJIC) and/or connexins, the gap junction proteins, is a hallmark of cancer. Restoration of GJIC and/or increase of connexin expression have been related to the reduction of tumorigenesis. Connexins have been reported as tumor suppressors due to both GJIC-independent and -dependent mechanisms. Therefore, development of effective agents or methods to enhance GJIC and restore connexin expression in cancer cells is a new strategy in cancer treatment. PQ1, 6-Methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethyl- phenyloxy)quinoline, has been demonstrated to increase GJIC, restore connexin expression, and exert anti-cancer effects on T47D breast cancer cells. Studies of apoptotic pathways showed that PQ1 activated both extrinsic and intrinsic apoptotic pathways, indicating that PQ1 exerts its anti- cancer effects via a GJIC-independent mechanism through the induction of apoptosis. Combinational treatment of PQ1 and cisplatin showed that PQ1 counteracted cisplatin-induced inhibition of GJIC and reduction of connexin expression, thereby increasing the efficacy of cisplatin in T47D cancer cells via a GJIC-dependent mechanism. Further studies of drug distribution and toxicity revealed that administration of PQ1 by oral gavage can be achieved with low toxicity to normal vital organs. All the results suggest that PQ1, a gap junction enhancer, can function as an anti-cancer agent and potentiate the efficacy of antineoplastic drugs via both GJIC-independent and -dependent pathways. GAP JUNCTION ENHANCER AS AN ANTI-CANCER AGENT VIA GJIC-INDEPENDENT AND -DEPENDENT PATHWAYS by YING DING B.E., Tianjin University, Tianjin, China, 2004 B.B.A., Tianjin University, Tianjin, China, 2004 M.S., Tianjin University, Tianjin, China, 2007 A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Biochemistry and Molecular Biophysics College of Arts and Sciences KANSAS STATE UNIVERSITY Manhattan, Kansas 2013 Approved by: Major Professor Thu Annelise Nguyen Abstract Gap junctions (GJ) are intercellular channels connecting adjacent cells, allowing small molecules to transport between cells, thereby maintaining all homeostasis. Loss of gap junctional intercellular communication (GJIC) and/or connexins, the gap junction proteins, is a hallmark of cancer. Restoration of GJIC and/or increase of connexin expression have been related to the reduction of tumorigenesis. Connexins have been reported as tumor suppressors due to both GJIC-independent and -dependent mechanisms. Therefore, development of effective agents or methods to enhance GJIC and restore connexin expression in cancer cells is a new strategy in cancer treatment. PQ1, 6-Methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethyl- phenyloxy)quinoline, has been demonstrated to increase GJIC, restore connexin expression, and exert anti-cancer effects on T47D breast cancer cells. Studies of apoptotic pathways showed that PQ1 activated both extrinsic and intrinsic apoptotic pathways, indicating that PQ1 exerts its anti- cancer effects via a GJIC-independent mechanism through the induction of apoptosis. Combinational treatment of PQ1 and cisplatin showed that PQ1 counteracted cisplatin-induced inhibition of GJIC and reduction of connexin expression, thereby increasing the efficacy of cisplatin in T47D cancer cells via a GJIC-dependent mechanism. Further studies of drug distribution and toxicity revealed that administration of PQ1 by oral gavage can be achieved with low toxicity to normal vital organs. All the results suggest that PQ1, a gap junction enhancer, can function as an anti-cancer agent and potentiate the efficacy of antineoplastic drugs via both GJIC-independent and -dependent pathways. Table of Contents List of Figures ................................................................................................................................ ix List of Tables ................................................................................................................................. xi Acknowledgements ....................................................................................................................... xii Dedication .................................................................................................................................... xiv Chapter 1 - Review of Literature .................................................................................................... 1 1.1 Gap Junctions and Connexins ............................................................................................... 1 1.1.1 Nomenclature and Distribution of Connexins ............................................................... 1 1.1.2 Structures of Connexins and Gap Junctions .................................................................. 4 1.1.3 Regulation Pathways of Connexins ............................................................................... 6 1.1.4 Functions of Gap Junctions .......................................................................................... 18 1.2 Gap Junctions and Diseases ................................................................................................ 20 1.2.1 Overview ...................................................................................................................... 20 1.2.2 Gap Junctions and Cancer ............................................................................................ 22 1.2.3 Gap Junctions and Breast Cancer ................................................................................ 28 1.3 Connexins and Gap Junctions as Therapeutic Targets ....................................................... 36 1.3.1 Therapeutic Approaches Related to GJIC .................................................................... 36 1.3.2 Therapeutic Approaches Related to Connexin Expression .......................................... 37 1.3.3 PQ1 as a Gap Junction Enhancer ................................................................................. 38 References ................................................................................................................................. 40 Chapter 2 - Hypotheses and Objectives ........................................................................................ 60 2.1 Hypotheses .......................................................................................................................... 60 2.2 Objectives ........................................................................................................................... 60 Chapter 3 - PQ1, a Quinoline Derivative, Induces Apoptosis in T47D Breast Cancer Cells through Activation of Caspase-8 and Caspase-9 ................................................................... 62 3.1 Abstract ............................................................................................................................... 62 3.2 Introduction ......................................................................................................................... 63 3.3 Meterial and Methods ......................................................................................................... 66 3.3.1 Reagents and Antibodies .............................................................................................. 66 3.3.2 Cell Line and Cell Culture ........................................................................................... 66 v 3.3.3 Cell Morphology .......................................................................................................... 66 3.3.4 Cell Viability Assay ..................................................................................................... 67 3.3.5 Flow Cytometry ........................................................................................................... 67 3.3.6 Mitochondria Isolation ................................................................................................. 67 3.3.7 Western Blot Analysis ................................................................................................. 68 3.3.8 Immunofluorescence and Confocal Microscopy ......................................................... 68 3.3.9 Caspase Inhibitor Assay ............................................................................................... 69 3.3.10 Statistical Analysis ..................................................................................................... 69 3.4 Results ................................................................................................................................. 70 3.4.1 PQ1 Changes Cell Morphology and Induces Cell Death in T47D Breast Cancer Cells ..............................................................................................................................................